Jefferies Assumes Aerovate Therapeutics at Buy, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Eun Yang has assumed coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and increased the price target to $65.
March 25, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Eun Yang has given Aerovate Therapeutics a Buy rating and raised the price target to $65.
The upgrade in rating and increase in price target by a reputable analyst like Eun Yang from Jefferies can lead to increased investor confidence in Aerovate Therapeutics, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100